Merck announced Wednesday that China has approved the male version of its Gardasil human papillomavirus (HPV) vaccine.

The U.S.-based pharmaceutical company reports that China's National Medical Products Administration (NMPA) has authorized the use of Gardasil in men aged 9 to 26 for the prevention of HPV-related diseases and cancers.

Gardasil thus becomes the first HPV vaccine for men approved in China.

Copyright (c) 2025 CercleFinance.com. All rights reserved.